Bristol-myers Company

Other

Bristol-myers Squibb Compnay

Maki Nishio

Toshikazu Oki

Takeo Miyaki

Yosuke Sawada

Masataka Konishi

Masatoshi Kakushima

Koji Tomita

Mitsuaki Tsunakawa

Kyoichiro Saitoh

Kozo Tomatsu

Seiji Iimura

Shigeyuki Ando

Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.

Method for treating fungal infections with serine analogs of BU-3608

Actinomadura hibisca microorganism useful for preparing serine analogs

Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.

Antifungal antibiotics

Disclosed herein are antibiotic BU-3608 D and E isolated from Actinomadura hibisca. These compounds are active antifungal agents.

Process for producing antibiotics BU-3608 D and BU-3608 E

Serine analogs of BU-3608 antibiotics

Disclosed herein are pradimicin amides which are active as antifungel agents.

Pradimicin amide derivatives

Antibiotics BU-3608D and BU-3608E

Disclosed herein are N-alkyl derivatives of antibiotics BU-3608, BU-3608 B, C, D and E as well as the corresponding desxylosyl compounds. These novel compounds are useful as antifungal agents.

BU-3608 derivatives

Novel antifungal antibiotic compounds have the structural formula ##STR1## A preferred compound where R is 4-hydroxypentyl is denoted BU-3557B.sub.2. A complex of said compounds is produced by fermenting a culture of Sacchrothrix aerocolonigenes strain N806-4 (ATCC 53712). The complex is recovered by adsorption on nonionic porous polymer resin adsorbent and individual component compounds exhibit in vitro activity against fungi and Gram-positive bacteria and BU-3557B.sub.2 demonstrates in vitro antiprotazoal activity. BU-3557B.sub.2 demonstrates in vivo activity against C. albicans vaginal infection and BU-3557A.sub.3 (where R is 1,5-dihydroxy-5,5-dimethylpentyl) demonstrates in vivo activity against C. albicans systemic infection.

Polysubstituted thiazolylpyridine carboxyamide antifungal antibiotic

Growing community of inventors

Tokyo, Japan

Maki Nishio